Nanologica AB Cash Flow Conversion Efficiency
Nanologica AB cash flow conversion efficiency. Based on the latest financial reports, Nanologica AB (NICA) has a cash flow conversion efficiency ratio of -0.064x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.22 Million ≈ $-669.05K USD) by net assets (Skr97.50 Million ≈ $10.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nanologica AB (2015–2025)
Cash flow conversion efficiency of Nanologica AB from 2015 to 2025. This chart illustrates how Nanologica AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NICA live share price for real-time trading data and today's change.
Nanologica AB Cash Flow Conversion Ratio Explained
Nanologica AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nanologica AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanologica AB ranked by their cash flow conversion efficiency. Also see how much is Nanologica AB worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orexo AB
ST:ORX
|
-0.344x |
|
Homebiogas Ltd
TA:HMGS
|
-0.172x |
|
Westbond Enterprises Corp
V:WBE
|
0.025x |
|
Garanti Yatirim Ortakligi AS
IS:GRNYO
|
0.026x |
|
Hiremii Ltd
AU:HMI
|
-0.436x |
|
Utilico Emerging Markets Ltd
LSE:UEM
|
0.009x |
|
ECS Botanics Holdings Ltd
AU:ECS
|
0.015x |
|
Battery Age Minerals Ltd
AU:BM8
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Nanologica AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Nanologica AB from 2015 to 2025. Review Nanologica AB (NICA) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr22.64 Million ≈ $2.44 Million |
Skr-39.88 Million ≈ $-4.29 Million |
-1.761x | -61.68% |
| 2024-12-31 | Skr74.11 Million ≈ $7.98 Million |
Skr-80.73 Million ≈ $-8.69 Million |
-1.089x | -105.77% |
| 2023-12-31 | Skr-1.90 Million ≈ $-204.26K |
Skr-35.85 Million ≈ $-3.86 Million |
18.887x | +3155.69% |
| 2022-12-31 | Skr73.16 Million ≈ $7.87 Million |
Skr-45.22 Million ≈ $-4.87 Million |
-0.618x | +31.41% |
| 2021-12-31 | Skr51.60 Million ≈ $5.55 Million |
Skr-46.49 Million ≈ $-5.00 Million |
-0.901x | -93.29% |
| 2020-12-31 | Skr92.97 Million ≈ $10.00 Million |
Skr-43.34 Million ≈ $-4.66 Million |
-0.466x | +83.33% |
| 2019-12-31 | Skr4.12 Million ≈ $443.48K |
Skr-11.52 Million ≈ $-1.24 Million |
-2.796x | -466.33% |
| 2018-12-31 | Skr23.71 Million ≈ $2.55 Million |
Skr-11.71 Million ≈ $-1.26 Million |
-0.494x | +95.87% |
| 2017-12-31 | Skr1.94 Million ≈ $208.60K |
Skr-23.19 Million ≈ $-2.50 Million |
-11.965x | -1036.92% |
| 2016-12-31 | Skr22.03 Million ≈ $2.37 Million |
Skr-23.19 Million ≈ $-2.50 Million |
-1.052x | -82.15% |
| 2015-12-31 | Skr24.14 Million ≈ $2.60 Million |
Skr-13.95 Million ≈ $-1.50 Million |
-0.578x | -- |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more